258 related articles for article (PubMed ID: 12421092)
1. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease.
Shetty A; Forbes A
Am J Pharmacogenomics; 2002; 2(4):215-21. PubMed ID: 12421092
[TBL] [Abstract][Full Text] [Related]
2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
3. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
4. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
5. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
6. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease.
Mascheretti S; Schreiber S
Pharmacogenomics; 2004 Jul; 5(5):479-86. PubMed ID: 15212584
[TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour?
Louis E; Peeters M; Franchimont D; Seidel L; Fontaine F; Demolin G; Croes F; Dupont P; Davin L; Omri S; Rutgeerts P; Belaiche J
Clin Exp Immunol; 2000 Jan; 119(1):64-8. PubMed ID: 10606965
[TBL] [Abstract][Full Text] [Related]
8. Transcending conventional therapies: the role of biologic and other novel therapies.
Sandborn WJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab.
Mascheretti S; Hampe J; Kühbacher T; Herfarth H; Krawczak M; Fölsch UR; Schreiber S
Pharmacogenomics J; 2002; 2(2):127-36. PubMed ID: 12049175
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF therapy for Crohn's disease.
D'Haens G
Curr Pharm Des; 2003; 9(4):289-94. PubMed ID: 12570820
[TBL] [Abstract][Full Text] [Related]
11. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
12. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
16. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
[TBL] [Abstract][Full Text] [Related]
17. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.
van Deventer SJ
Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():3-8; discussion 38. PubMed ID: 10597333
[TBL] [Abstract][Full Text] [Related]
18. Infliximab as disease-modifying therapy.
D'Haens GR
Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):233-7. PubMed ID: 12610316
[TBL] [Abstract][Full Text] [Related]
19. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease.
Taylor KD; Plevy SE; Yang H; Landers CJ; Barry MJ; Rotter JI; Targan SR
Gastroenterology; 2001 May; 120(6):1347-55. PubMed ID: 11313304
[TBL] [Abstract][Full Text] [Related]
20. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease.
Bell SJ; Kamm MA
Aliment Pharmacol Ther; 2000 May; 14(5):501-14. PubMed ID: 10792111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
